Evid Based Med 17:195-196 doi:10.1136/ebmed-2012-100779
  • Economic analysis

Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

  1. Gavin Clunie
  1. Department of Rheumatology, The Ipswich Hospital, Ipswich, UK
  1. Correspondence to: Gavin Peter Ross Clunie
    Department of Rheumatology, The Ipswich Hospital, Heath Rd, Ipswich, Suffolk IP4 5PD, UK; gavin.clunie{at}

Commentary on:


Postmenopausal osteoporosis (PMO) related fractures are common, preventable and costly. Their prevention is a goal for healthcare agencies worldwide. Data to support screening of women are however weak and controversy surrounds whether to screen and, if so, at what age? The recommendation for, and justification of, resources for screening depends importantly on the cost-effectiveness of any screening method compared with alternatives including no screening.

The cost-effectiveness of screening needs to be considered within a complex landscape of medicosocial, financial and practical issues relevant to the healthcare system in which it operates. Accordingly, this analysis by Nayak et al is the most comprehensive attempt to date, to model the costs of screening for PMO.


The models estimated the costs (US$) of various screening methods …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article